Versant Venture Capital VI, L.P.'s Form 4 filing
Black Diamond Therapeutics, Inc.BDTX · filed Aug 30, 2024
- Accession no.
- 0000950170-24-102354
- Filed
- Aug 30, 2024, 4:16 PM ET
- Trade date
- Aug 28, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.40M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Versant Venture Capital VI, L.P.CIK 0001687880 | 10% Owner |
| Versant Voyageurs I, L.P.CIK 0001745960 | 10% Owner |
| Versant Voyageurs I Parallel, L.P.CIK 0001745961 | 10% Owner |
| Versant Vantage I, L.P.CIK 0001765253 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 28, 2024 | Common Stock | SSaleDisposed | −221,600 | $6.32F1 | −$1,400,556.32 | 3,726,341 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.32 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Referenced by the price of 1 transaction in Table I.